

# SPDR<sup>®</sup> S&P<sup>®</sup>

## Pharmaceuticals ETF

### Key Features

- The SPDR<sup>®</sup> S&P<sup>®</sup> Pharmaceuticals ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P<sup>®</sup> Pharmaceuticals Select Industry<sup>®</sup> Index (the "Index")
- Seeks to provide exposure to the pharmaceuticals segment of the S&P TMI, which comprises the Pharmaceuticals sub-industry
- Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks
- Allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing

### About This Benchmark

The S&P Pharmaceuticals Select Industry Index (the "Index") represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). The S&P TMI is designed to track the broad U.S. equity market. The pharmaceuticals segment of the S&P TMI comprises the Pharmaceuticals sub-industry. The Index is one of twenty-one (21) of the S&P Select Industry Indices (the "Select Industry Indices"), each designed to measure the performance of a narrow sub-industry or group of sub-industries determined based on the Global Industry Classification Standard ("GICS").

### Fund Information

Inception Date	06/19/2006
CUSIP	78464A722

# XPH

Fact Sheet

Equity

As of 03/31/2023

### Total Return (As of 03/31/2023)

	NAV (%)	Market Value (%)	Index (%)
<b>Cumulative</b>			
QTD	0.42	0.40	0.42
YTD	0.42	0.40	0.42
<b>Annualized</b>			
1 Year	-7.98	-8.00	-8.39
3 Year	5.47	5.46	5.44
5 Year	0.51	0.52	0.53
10 Year	4.74	4.74	4.83

### Gross Expense Ratio (%)

0.35

### 30 Day SEC Yield (%)

1.07

**Past performance is not a reliable indicator of future performance. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. All results are historical and assume the reinvestment of dividends and capital gains. Visit [ssga.com](http://ssga.com) for most recent month-end performance. Performance is shown net of fees. Performance of an index is not illustrative of any particular investment. It is not possible to invest directly in an index. Index returns are unmanaged and do not reflect the deduction of any fees or expenses. Index returns reflect all items of income, gain and loss and the reinvestment of dividends and other income as applicable.**

### Characteristics

Est. 3-5 Year EPS Growth	16.21%
Index Dividend Yield	1.27%
Price/Earnings Ratio FY1	10.67
Number of Holdings	40
Price/Book Ratio	2.62
Average Market Cap (M)	US\$68,289.47

Top 10 Holdings	Weight (%)
Jazz Pharmaceuticals Public Limited Company	4.50
Eli Lilly and Company	4.50
Royalty Pharma Plc Class A	4.49
Axsome Therapeutics Inc.	4.36
Bristol-Myers Squibb Company	4.35
Organon & Co.	4.28
Pfizer Inc.	4.27
Zoetis Inc. Class A	4.25
Johnson & Johnson	4.22
Merck & Co. Inc.	4.07

Totals may not equal 100 due to rounding.

## ssga.com

### Information Classification: General

#### State Street Global Advisors

One Iron Street, Boston MA 02210  
T: +1 866 787 2257

#### Glossary

**NAV** The market value of a mutual fund's or ETFs total assets, minus liabilities, divided by the number of shares outstanding.

**Market Value** Determined by the midpoint between the bid/offer prices as of the closing time of the New York Stock Exchange (typically 4:00PM EST) on business days.

**Gross Expense Ratio** The fund's total annual operating expense ratio. It is gross of any fee waivers or expense reimbursements. It can be found in the fund's most recent prospectus.

**30 Day SEC Yield** (Also known as Standardized Yield) An annualized yield that is calculated by dividing the net investment income earned by the fund over the most recent 30-day period by the current maximum offering price.

**Est. 3-5 Year EPS Growth** Based on the underlying holdings of the fund. The actual earnings estimates for the underlying holdings are provided by FactSet, First Call, I/B/E/S Consensus, and Reuters and are used to calculate a mean 3-5 year EPS growth rate estimate.

**Index Dividend Yield** The weighted average of the underlyings' indicated annual dividend divided by price, expressed as a percentage.

**Price/Earnings Ratio FY1** The weighted harmonic average of current share price divided by the forecasted one year earnings per share for each security in the fund. Negative and positive outliers are included in the calculation.

**Price/Book Ratio** The weighted harmonic

average of closing market price divided by the most recent reported book value for each security in the fund's portfolio as calculated for the last twelve months.

#### Important Risk Information

Weights are as of the date indicated, are subject to change, and should not be relied upon as current thereafter. Investing involves risk including the risk of loss of principal.

The information provided does not constitute investment advice and it should not be relied on as such. It should not be considered a solicitation to buy or an offer to sell a security. It does not take into account any investor's particular investment objectives, strategies, tax status or investment horizon. You should consult your tax and financial advisor.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without SSGA's express written consent.

This communication is not intended to be an investment recommendation or investment advice and should not be relied upon as such. The Fund's investments are subject to changes in general economic conditions, general market fluctuations and the risks inherent in investment in securities markets. Investment markets can be volatile and prices of investments can change substantially due to various factors including, but not limited to, economic growth or recession, changes in interest rates, changes in the actual or perceived creditworthiness of issuers, and general market liquidity. The Fund is subject to the risk that geopolitical events will disrupt securities markets and adversely affect global economies and markets. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, or other events could have a significant impact on the Fund and its investments.

**Equity securities** may fluctuate in value and can decline significantly in response to the activities of individual companies and general market and economic conditions.

Funds investing in a **single sector** may be subject to more volatility than funds investing in a diverse group of sectors. Because of their narrow focus, **sector funds** tend to be more volatile than broadly diversified funds and generally result in greater price fluctuations than the overall market. The Fund is classified as "diversified" under the Investment Company Act of 1940, as amended (the "1940 Act"); however, the Fund may become "non-diversified," as defined under the 1940 Act, solely as a result of tracking the Index (e.g., changes in weightings of one or more component securities). When the Fund is non-diversified, it may invest a relatively high percentage of its assets in a limited number of issuers.

**Passively managed funds** invest by sampling the index, holding a range of securities that, in the aggregate, approximates the full Index in terms of key risk factors and other characteristics. This may cause the fund to experience tracking errors relative to performance of the index. While the shares of ETFs are tradable on secondary markets, they may not readily trade in all market conditions and may trade at significant discounts in periods of **market stress**.

**ETFs** trade like stocks, are subject to investment risk, fluctuate in market value and may trade at prices above or below the ETFs net asset value. Brokerage commissions and ETF expenses will reduce returns.

**Intellectual Property Information:** The S&P 500<sup>®</sup> Index is a product of S&P Dow Jones Indices LLC or its affiliates ("S&P DJI") and have been licensed for use by State Street Global Advisors. S&P, SPDR, S&P 500, US 500 and the 500 are trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones<sup>®</sup> is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones") and

has been licensed for use by S&P Dow Jones Indices; and these trademarks have been licensed for use by S&P DJI and sublicensed for certain purposes by State Street Global Advisors. The fund is not sponsored, endorsed, sold or promoted by S&P DJI, Dow Jones, S&P, their respective affiliates, and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of these indices. The S&P Select Industry Index series is designed to measure the performance of narrow GICS (Global Industry Classification Standard) sub-industries. The S&P Pharmaceuticals Select Industry Index is an equal-weighted index that draws constituents from the pharmaceuticals segment of the S&P TMI. Liquidity and market capitalization screens are applied to the index to ensure investability.

**Distributor** State Street Global Advisors Funds Distributors, LLC, member FINRA, SIPC, an indirect wholly owned subsidiary of State Street Corporation. References to State Street may include State Street Corporation and its affiliates. Certain State Street affiliates provide services and receive fees from the SPDR ETFs.

**Before investing, consider the funds' investment objectives, risks, charges and expenses. To obtain a prospectus or summary prospectus which contains this and other information, call 1-866-787-2257 or visit ssga.com. Read it carefully. Not FDIC Insured No Bank Guarantee May Lose Value**

© 2023 State Street Corporation. All Rights Reserved. Tracking Number: 3414969.4.3.AM.RTL Expiration Date: 07/31/2023 ETF-XPH 20230419/17:38